TORONTO, Jan. 15, 2014 /PRNewswire/ -- According to Millennium Research Group (MRG), the global authority on medical technology market intelligence, the United States and European transcatheter embolization and occlusion (TEO) device markets will expand moderately through 2022, with embolization particles representing one of the fastest-growing segments. In particular, increasing interest in drug-eluting beads (DEBs) and radioembolization spheres in interventional oncology has fueled rapid growth of these markets.
The European radioembolization sphere market will be further boosted by expansion in the United Kingdom a result of the National Health Service's (NHS) Commissioning through Evaluation program, which will evaluate radioembolization as a treatment for liver cancer and fund its use in a small number of patients. While the NHS has yet to decide on widespread coverage of radioembolization, the program will improve awareness of the procedure and encourage other countries to consider expanding reimbursement.
In both the US and Europe, there is considerable competitive activity in the embolization particle market. A recent acquisition made by BTG in the radioembolization space and the US launch of a new DEB product, ONCOZENE, by CeloNova BioSciences have reshaped the competitive landscape. Competitive dynamics are also shifting in the peripheral vascular (PV) plug space. Although St. Jude Medical's AMPLATZER line has historically held a monopoly, in 2013, Reverse Medical's Micro Vascular Plug gained US and European approval, and EndoShape's Medusa Vascular gained approval in the US. ArtVentive Medical Group's EOS device, which is increasingly being used in Europe in the emerging pelvic congestion syndrome indication, will also likely enter the US market in the near future.
"While St. Jude Medical dominated the PV plug market in 2013, we'll start to see the impact of new entrants in 2014," said MRG Senior Analyst Sean Messenger. "These smaller, innovative PV plug companies represent attractive acquisition targets for PV coil companies that want to offer comprehensive product portfolios in the TEO space."
Millennium Research Group's US Markets for Transcatheter Embolization and Occlusion Devices 2014 and European Markets for Transcatheter Embolization and Occlusion Devices 2014 reports include unit, procedure, average selling price and revenue information, along with market drivers and limiters and a competitive landscape for interventional neuroradiology (INR) embolization coils, INR coiling-assist devices, INR flow-diverting devices, PV embolization coils, PV plugs, embolization particles, liquid embolics and accessory devices in the United States, France, Germany, Italy, Spain and the United Kingdom. Supplemental country coverage is also available for Austria, Belgium, the Czech Republic, Denmark, Finland, Greece, Hungary, the Netherlands, Norway, Poland, Portugal, Romania, Sweden, Switzerland and Ukraine, as well as in aggregate for the rest of the European countries.
About Millennium Research Group
Millennium Research Group (www.MRG.net), a Decision Resources Group company (www.DecisionResourcesGroup.com), is the global authority on medical technology market intelligence and the leading provider of strategic information to the healthcare sector. The company provides specialized industry expertise through multiclient market research, ongoing Marketrack™ projects, customer loyalty tracking, facility-level procedure forecasting, and customized solutions.
About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information, and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.
All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.
For more information, contact:
SOURCE Millennium Research Group